Trial Profile
Study to assess the effectiveness of esomeprazole 40 mg once daily in subjects with continuing gastroesophageal reflux disease (GORD) symptoms following treatment with a previous full dose proton pump inhibitor (PPI)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Aug 2019
Price :
$35
*
At a glance
- Drugs Esomeprazole (Primary)
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- Acronyms RESPONSE
- Sponsors AstraZeneca
- 21 Dec 2006 New trial record.